2026 BSSM Position Statement: Potential Use of Enclomiphene in Male Hypogonadism

Full title: Position Statement on the Potential Application of Enclomiphene in the Management of Male Hypogonadism, British Society for Sexual Medicine (BSSM), published in World Journal of Men’s Health, 2026 Core positioning: Enclomiphene is an emerging off-label SERM option, NOT standard first-line therapy for male hypogonadism. It is reserved for carefully selected men with secondary (hypothalamic-pituitary) hypogonadism, especially those who desire fertility preservation. BSSM emphasizes intact hypothalamic-pituitary-testicular (HPT) axis is a prerequisite; it cannot replace established therapies (TRT, hCG/FSH). Aligned with SIAMS 2026 gynecomastia guideline, OMA 2026 obesity & CVD statement, ACP 2026 obesity pharmacotherapy guideline, for management of obesity-related functional hypogonadism.

1. Mechanism & Pharmacology

Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM).

• Blocks oestrogen negative feedback at hypothalamus/pituitary → increases endogenous LH and FSH secretion → stimulates Leydig cells to produce testosterone and sustains spermatogenesis.
• Key distinction from exogenous testosterone replacement (TRT): TRT suppresses HPT axis and impairs sperm production; enclomiphene preserves or improves spermatogenesis.
• Pharmacology: shorter half-life (~10.5 h), primarily oestrogen antagonist; avoids the oestrogen-agonist effects of zuclomiphene (cis-isomer of clomiphene).

2. Candidate Selection (Critical Pre-Triage)

✅ Suitable candidates (BSSM potential use population)

1. Secondary hypogonadism：repeated morning low total testosterone, LH/FSH low or inappropriately normal, intact testicular function;
2. Fertility preservation priority: men requiring testosterone normalization while attempting conception;
3. Functional hypogonadism related to obesity, metabolic syndrome, T2DM (common clinical scenario, cross-reference OMA/ACP obesity guidelines);
4. Intolerance to injectable/topical testosterone formulations, or unwilling to receive lifelong TRT.

❌ Not suitable / poor responders

1. Primary hypogonadism (testicular failure, elevated baseline LH/FSH): testes cannot respond to gonadotropin stimulation; minimal benefit;
2. Organic pituitary mass, severe pituitary damage;
3. Active prostate cancer, high-grade prostate intraepithelial neoplasia (PIN);
4. Uncontrolled liver disease;
5. Desire for rapid testosterone correction (slower onset than TRT).

Important note: BSSM highlights that obesity-related functional hypogonadism should first receive lifestyle/weight-loss intervention (GLP‑1, calorie deficit) before considering enclomiphene.

3. Dose Regimen & Titration (Off-label, expert consensus-based)

• Starting dose: 12.5 mg once daily oral;
• Titration: after 4–6 weeks, if testosterone remains suboptimal, increase to 25 mg daily; maximum recommended daily dose 25 mg.
• Discontinue if no biochemical response after 8–12 weeks at 25 mg daily.
• Administer once daily; can be taken with or without food.

4. Baseline Assessment & Monitoring Protocol

Baseline workup before initiation

• Morning total testosterone, LH, FSH, SHBG, oestradiol, PSA, liver function, full blood count;
• Semen analysis for patients pursuing fertility;
• History: prostate disease, liver disease, medications, BMI, metabolic screening (glucose/HbA1c, lipids).

Follow-up schedule

1. 4–6 weeks after starting / dose adjustment: total testosterone, LH, FSH, oestradiol; assess symptoms and adverse events;
2. 3 months: repeat hormone panel, PSA, LFT; semen analysis if fertility goal;
3. Long-term maintenance: every 6 months hormone and PSA monitoring; annual liver function.

5. Safety & Adverse Events

Common, usually mild and reversible:

• Hot flushes, mood lability, headache, visual disturbance (rare, SERM class effect; stop and review if visual changes);
• Elevated oestradiol, risk of breast tenderness/gynecomastia (cross-reference SIAMS 2026 gynecomastia guideline);
• Potential increase in lipid or hepatic enzyme.

Key safety warnings:

• No long-term (≥5 years) prostate/cardiovascular hard endpoint data;
• Not approved as a licensed medicine in the UK; use remains off-label, requires formal shared decision-making, written informed consent;
• Do not use in men with untreated prostate malignancy.

6. Comparison with Established Treatments

1. TRT: rapid testosterone rise; suppresses HPT and spermatogenesis; ideal for men without fertility plans.
2. hCG ± FSH: gold standard for fertility treatment in secondary hypogonadism; injectable, higher cost.
3. Enclomiphene: oral, preserves spermatogenesis; slower onset, off-label, limited long-term safety data.

BSSM’s core recommendation: enclomiphene is not to replace hCG/FSH for infertility, but can be considered an alternative oral option in selected patients after shared decision-making.

7. Special Populations

1. Obesity / T2DM functional hypogonadism: weight reduction is first-line; enclomiphene may be added if hypogonadism persists after structured lifestyle/GLP‑1 intervention;
2. Older men (>65): more cautious, strict PSA and prostate assessment, lower threshold for discontinuation;
3. Previous anabolic steroid-induced HPT suppression: may be considered as HPT recovery agent, only after specialist andrology assessment;
4. Infertility couples: joint review with reproductive medicine specialist, semen monitoring mandatory.

8. Evidence Gaps

1. Large-scale, long-term RCTs on cardiovascular and prostate safety;
2. Optimal duration of maintenance therapy; relapse rate after stopping enclomiphene;
3. Head-to-head comparison vs hCG/FSH on pregnancy rates;
4. Safety in men with pre-existing CVD (cross-reference OMA obesity-CVD statement).

9. Cross-reference with guideline series

1. BSSM 2026 this statement: enclomiphene for secondary male hypogonadism, fertility-preserving off-label option;
2. SIAMS 2026 gynecomastia guideline: monitoring for SERM-related breast tenderness/gynecomastia;
3. OMA 2026 Obesity & CVD statement: obesity-related functional hypogonadism and metabolic risk reduction;
4. ACP 2026 obesity pharmacotherapy: GLP‑1 as primary therapy for obese patients with functional hypogonadism;
5. EASO/EFAD/ECPO 2026 incretin consensus: nutritional and body composition support during obesity management.

Disclaimer: This summary is for academic study only. Enclomiphene is off-label therapy in the UK; prescription must be undertaken by an andrology/sexual medicine MDT, after full shared decision-making and exclusion of contraindications